About NovoMix 70 FlexPen Novo Nordisk
NovoMix 70 FlexPen is a biphasic insulin preparation manufactured by Novo Nordisk, specifically formulated for advanced laboratory research into insulin pharmacology and metabolic pathway analysis. This preparation combines rapid-acting insulin aspart with protamine-crystallised insulin aspart in a 30:70 ratio, providing researchers with a dual-phase insulin profile for comprehensive metabolic studies. The FlexPen delivery system offers precise dosing capabilities essential for controlled laboratory investigations. Research scientists examining glucose homeostasis, insulin receptor binding kinetics, and pancreatic beta-cell function modelling utilise this pharmaceutical-grade preparation across various experimental protocols. Available through Stroid UK Shop, this research tool supports investigations into diabetes pathophysiology and insulin signalling cascades.
Laboratory Applications
Research laboratories employ NovoMix 70 FlexPen preparations to investigate biphasic insulin release patterns and their effects on cellular glucose uptake mechanisms. The formulation enables researchers to study both immediate and extended insulin activity profiles in experimental models examining metabolic dysfunction. Scientists investigating insulin resistance pathways, glucose transporter expression, and adipocyte metabolism utilise this preparation for time-course studies requiring controlled insulin exposure. The preparation supports research into insulin pharmacokinetics, receptor binding affinity studies, and post-receptor signalling pathway analysis. Advanced metabolic research facilities examining pancreatic islet function and glucose homeostasis regulation incorporate this insulin preparation into their experimental protocols. Researchers can explore this preparation alongside other metabolic modulators available in our insulin research category, complementing investigations with selective androgen receptor modulators and research peptides for comprehensive metabolic studies.
Technical Specifications
| Parameter | Specification |
|---|---|
| Manufacturer | Novo Nordisk |
| Insulin Type | Biphasic insulin aspart |
| Composition Ratio | 30% insulin aspart, 70% protamine-crystallised insulin aspart |
| Delivery System | FlexPen pre-filled device |
| Storage Requirements | 2-8°C, protect from light |
| Research Applications | Insulin pharmacology, glucose metabolism studies |
| Quality Standards | Pharmaceutical grade, research use only |
Research Compliance Statement
NovoMix 70 FlexPen is supplied exclusively for in-vitro laboratory research purposes and cellular studies investigating insulin pharmacology and metabolic pathways. This preparation is not intended for human consumption, clinical application, or any form of in-vivo administration. Research institutions must ensure appropriate laboratory protocols, proper storage conditions, and compliance with institutional research guidelines when handling this insulin preparation. All investigations must be conducted by qualified research personnel within controlled laboratory environments following established research protocols for insulin-based studies.
